Adaptive radiotherapy using a new linear accelerator for cancer treatment
A Prospective Study on Online Adaptive Radiotherapy (ART) Using the ETHOS Linear Accelerator for Various Tumor Entities and the Feasibility of Integrating Multi-Parametric Patient Data Into the Adaptive Workflow
Charite University, Berlin, Germany · NCT06116019
This study is testing a new way to adjust radiation therapy for cancer patients each day based on changes in their tumors to see if it improves treatment.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 649 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Charite University, Berlin, Germany (other) |
| Drugs / interventions | radiation |
| Locations | 1 site (Berlin) |
| Trial ID | NCT06116019 on ClinicalTrials.gov |
What this trial studies
This study evaluates the use of the Varian/SHS ETHOS treatment system for online adaptive radiotherapy (ART) in patients with various types of cancer. It aims to dynamically adjust radiation treatment plans on a daily basis to accommodate changes in tumor size or position, utilizing cone beam computed tomography for real-time imaging. The study will assess the feasibility and acceptability of ART across different tumor types and integrate patient-reported outcomes to enhance treatment monitoring. This is an observational study that will gather data over several weeks of therapy.
Who should consider this trial
Good fit: Ideal candidates include adult patients over 18 years old with any tumor type requiring radiotherapy or chemoradiotherapy.
Not a fit: Patients who are pregnant or unable to provide informed consent will not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to more precise and effective radiation therapy, improving treatment outcomes for cancer patients.
How similar studies have performed: While the concept of adaptive radiotherapy is established, the specific application of the ETHOS system represents a novel approach that has not been widely tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult patients (\>18 years) * All tumor entities with an indication for radiotherapy and/or chemoradiotherapy * Signed informed consent Exclusion Criteria: * Pregnancy * Patients who are not capable of giving consent
Where this trial is running
Berlin
- Charité - Universitätsmedizin — Berlin, Germany (RECRUITING)
Study contacts
- Study coordinator: Goda Kalinauskaite, MD
- Email: goda.kalinauskaite@charite.de
- Phone: +49 30 450 527318
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Prostate Cancer, Head and Neck Cancer, NSCLC, SCLC, Esophageal Cancer, Bladder Cancer, Rectum Cancer, Cervix Cancer